Recursion Director Sells $924K in Stock; Company Posts Heavy Cash Burn Amid Early Clinical Wins
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals on February 3, 2026, for $4.20 per share, a transaction valued at $924,000 executed under a Rule 10b5-1 trading plan. The sale occurred while the stock has declined 5% over the past week and 45% year-over-year, trading at $3.96 — below Borgeson’s sale price. Post-sale, Borgeso…